Bengaluru develops a Covid-19 vaccine that tolerates heat

Bengaluru develops a Covid-19 vaccine that tolerates heat

Initiation launched at the Indian Institute of Science (IISc), Bangalore, is developing a Covid-19 vaccine that can be stored at 37 degrees Celsius, a development that could transform the game in India without adequate cold resources

Bengaluru develops a Covid-19 vaccine that tolerates Heat Tolerant COVID-19 vaccine developed for IISc-linked startups

The COVID-19 vaccine, which can be stored at 37º C, was first developed at the Indian Institute of Science (IISc), Bangalore. This could change the game in India, which does not have enough resources for cold chains.

Raghavan Varadarajan, a biophysicist, co-founder, and head of startup Mynvax, said all hopes of vaccinating COVID-19 currently in clinical trials require at least 4º C temperatures. However, this novel vaccine does not require such conditions. Any other person entering the vaccine did not show that they had the same temperature data. The vaccine was kept at temperatures much higher than 37º C for a while, and it was fine.

In addition, this heat tolerant vaccine can withstand up to 70º C for up to 16 hours. In contrast, the former runner, AstraZeneca-Oxford's Covishield vaccine, produced by the Serum Institute of India, will have to be refrigerated at 2-8º C.

To put things in perspective, Karnataka has 2,900 cool areas. About 10.52 children lakh for about 16 years are vaccinated under the standard annual immunization programs in addition to pregnant women.

However, with the COVID-19 vaccine, the state needs formal chemical structures to house all of its 7.07 crores.

Vadarajan's team conducted an in-depth study of Guinea's rats and pigs on encouraging results. Currently, challenging studies in hamsters are ongoing, and animal testing is expected to be completed by December. The final formulation will also be further developed through studies, including process improvement, animal safety, toxicity, and finally, clinical trials.

Recently, Myynvax received another grant from IISc however, the weight of the COVID-19 vaccine made so far was made with the company's own money.

Varadarajan said that in the administration of the vaccine in human clinical trials, Rs 15 crore was needed. Vaccination can be guaranteed by mid-2022 if all goes well.